000286992 001__ 286992
000286992 005__ 20241113141212.0
000286992 0247_ $$2doi$$a10.1136/jitc-2023-007635
000286992 0247_ $$2pmid$$apmid:38199608
000286992 0247_ $$2altmetric$$aaltmetric:158274739
000286992 037__ $$aDKFZ-2024-00109
000286992 041__ $$aEnglish
000286992 082__ $$a610
000286992 1001_ $$00000-0003-4876-802X$$aPenack, Olaf$$b0
000286992 245__ $$aEndothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study.
000286992 260__ $$aLondon$$bBioMed Central$$c2024
000286992 3367_ $$2DRIVER$$aarticle
000286992 3367_ $$2DataCite$$aOutput Types/Journal article
000286992 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1705044726_11435
000286992 3367_ $$2BibTeX$$aARTICLE
000286992 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000286992 3367_ $$00$$2EndNote$$aJournal Article
000286992 520__ $$aWe previously reported that the 'Endothelial Activation and Stress Index' (EASIX; ((creatinine×lactate dehydrogenase)÷thrombocytes)) measured before start of conditioning predicts mortality after allogeneic hematopoietic stem cell transplantation (alloSCT) when used as continuous score. For broad clinical implementation, a prospectively validated EASIX-pre cut-off is needed that defines a high-risk cohort and is easy to use.In the current study, we first performed a retrospective cohort analysis in n=2022 alloSCT recipients and identified an optimal cut-off for predicting non-relapse mortality (NRM) as EASIX-pre=3. For cut-off validation, we conducted a multicenter prospective study with inclusion of n=317 first alloSCTs from peripheral blood stem cell in adult patients with acute leukemia, lymphoma or myelodysplastic syndrome/myeloproliferative neoplasms in the European Society for Blood and Marrow Transplantation network.Twenty-three % (n=74) of alloSCT recipients had EASIX-pre ≥3 taken before conditioning. NRM at 2 years was 31.1% in the high EASIX group versus 11.5% in the low EASIX group (p<0.001). Patients with high EASIX-pre also had worse 2 years overall survival (51.6% vs 70.9%; p=0.002). We were able to validate the cut-off and found that EASIX ≥3 was associated with more than twofold increased risk for NRM in multivariate analysis (HR=2.18, 95% CI 1.2 to 3.94; p=0.01). No statistically significant difference could be observed for the incidence of relapse.The results of this study provide a prospectively validated standard laboratory biomarker index to estimate the transplant-related mortality risk after alloSCT. EASIX ≥3 taken before conditioning identifies a population of alloSCT recipients who have a more than twofold increased risk of treatment-related mortality.
000286992 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000286992 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000286992 650_7 $$2Other$$aHematologic Neoplasms
000286992 650_7 $$2Other$$aImmunotherapy
000286992 650_7 $$2Other$$aInflammation
000286992 7001_ $$aLuft, Thomas$$b1
000286992 7001_ $$aPeczynski, Christophe$$b2
000286992 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b3$$udkfz
000286992 7001_ $$aSica, Simona$$b4
000286992 7001_ $$aArat, Mutlu$$b5
000286992 7001_ $$aItäla-Remes, Maija$$b6
000286992 7001_ $$aCorral, Lucia López$$b7
000286992 7001_ $$aSchaap, Nicolaas P M$$b8
000286992 7001_ $$aKaras, Michal$$b9
000286992 7001_ $$aRaida, Ludek$$b10
000286992 7001_ $$aSchroeder, Thomas$$b11
000286992 7001_ $$aDreger, Peter$$b12
000286992 7001_ $$aMetafuni, Elisabetta$$b13
000286992 7001_ $$aOzcelik, Tulay$$b14
000286992 7001_ $$aSandmaier, Brenda M$$b15
000286992 7001_ $$aKordelas, Lambros$$b16
000286992 7001_ $$aMoiseev, Ivan$$b17
000286992 7001_ $$aSchoemans, Hélène$$b18
000286992 7001_ $$aKoenecke, Christian$$b19
000286992 7001_ $$aBasak, Grzegorz W$$b20
000286992 7001_ $$aPeric, Zinaida$$b21
000286992 773__ $$0PERI:(DE-600)2719863-7$$a10.1136/jitc-2023-007635$$gVol. 12, no. 1, p. e007635 -$$n1$$pe007635$$tJournal for ImmunoTherapy of Cancer$$v12$$x2051-1426$$y2024
000286992 8564_ $$uhttps://inrepo02.dkfz.de/record/286992/files/e007635.full.pdf
000286992 8564_ $$uhttps://inrepo02.dkfz.de/record/286992/files/e007635.full.pdf?subformat=pdfa$$xpdfa
000286992 909CO $$ooai:inrepo02.dkfz.de:286992$$pVDB
000286992 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000286992 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000286992 9141_ $$y2024
000286992 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ IMMUNOTHER CANCER : 2022$$d2023-08-19
000286992 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-19
000286992 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-19
000286992 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-19
000286992 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T08:46:44Z
000286992 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T08:46:44Z
000286992 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T08:46:44Z
000286992 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-19
000286992 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-19
000286992 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-19
000286992 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-19
000286992 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-19
000286992 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-19
000286992 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ IMMUNOTHER CANCER : 2022$$d2023-08-19
000286992 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-19
000286992 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-19
000286992 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000286992 980__ $$ajournal
000286992 980__ $$aVDB
000286992 980__ $$aI:(DE-He78)C060-20160331
000286992 980__ $$aUNRESTRICTED